Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0

Kaohsiung Journal of Medical Sciences

Volumn 23, Issue 7, 2007, Pages 332-338

  Hsieh, Ming Yen ^a,c   Lee, Li Po ^a   Hou, Nai Jen ^a,b   Yang, Jeng Fu ^a   Huang, Jee Fu ^a,b,c   Dai, Chia Yen ^b,c   Chuang, Wan Long ^a,c   Lin, Zu Yau ^a,c   Chen, Shinn Cherng ^a,c   Hsieh, Ming Yuh ^a,c   Wang, Liang Yen ^a,c   Chang, Wen Yu ^a,c   Yu, Ming Lung ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatitis C virus; Hepatitis C virus RNA; Interferon therapy; Qualitative hepatitis C virus RNA assay

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS RNA;

ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; HEPATITIS B; HEPATITIS C; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL INSTRUMENTATION; PERFORMANCE; QUALITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VIRUS DETECTION;

EID: 34547736981     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(09)70418-8     Document Type: Article

References (18)

1. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999;31(Suppl 1):3-8.
2. Habib M, Mohamed MK, Abdel-Aziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001;33:248-53.
3. Carithers RL, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis 2000;20:159-71.
4. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.
5. Fried MW, Shiftman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
6. Doglio A, Laffont C, Caroli-Bosc FX, et al. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999;37:1567-9.
7. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
8. Trabaud MA, Bailly F, Si-Ahmed SN, et al. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon. J Clin Microbiol 1997;52:105-12.
9. Albadalejo J, Alonso R, Antinozzi R, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 1998;36:862-5.
10. Lunel F, Cresta P, Vitour D, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Hepatology 1999;29:528-35.
11. Lee SC, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000;38:4171-9.
12. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
13. Rossini A, Artini M, Levrero M, et al. Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. Dig Dis Sci 2001;46:2389-95.
14. Toyoda H, Kumada T, Nakano S, et al. Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1997;9:245-9.
15. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999;31(Suppl 1):237-43.
16. Carlsson T, Reichard O, Norkrans G, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005;12:473-80.
17. Kakumu S, Aiyama T, Okumura A, et al. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997;12:468-72.
18. Kawai S, Yokosuka O, Imazeki F, et al. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level. J Med Virol 2002;68:343-51.